The efficacy of Rofecoxib, even in a relatively lower
daily dose of 12.5 mg, is similar to that of Diclofenac
in popular routine daily dose of 100 mg slow release
in the symptomatic management of OA knees. Even at 4
weeks usage, Rofecoxib has a superior safety profile
compared to Diclofenac.
Abstracts – 10th Asia Pacific
League of Associations for Rheumatology Congress 2002;